Anthropic Sets Up Bay Area Wet Lab to Extend AI Work into Biology

Anthropic has quietly established a wet lab in the San Francisco Bay Area, extending its artificial intelligence work into hands-on biology and drug science, according to Reuters sources.

The company’s life sciences lead, Eric Coadler-Abrams, confirmed the lab’s existence, saying biological research ultimately needs to be tested in real laboratory settings. He said Anthropic is doing this work now, with a model similar to most biotech companies—some work is done at its own facilities, while some is conducted with external partners. A spokesperson added that the lab is not specifically for drug discovery but declined to elaborate.

People familiar with the matter described the wet lab as a small step toward Anthropic’s broader goal of addressing diseases it believes the pharmaceutical industry has neglected. The company has also said it hopes to support the development of rare disease treatments and deliver results before employees and the public lose confidence in AI’s value. Drug development carries no guarantee of success, and most drug candidates ultimately fail clinical safety and efficacy trials.

For Anthropic CEO Dario Amodei, the effort has personal significance. He recently wrote that his father died of a disease for which a treatment appeared just a few years later. Coadler-Abrams echoed that sentiment, saying Anthropic’s mission is to develop powerful AI in a way that genuinely benefits the world, and that life sciences represents one of the largest opportunities to achieve that.